Blossom

What Blossom does

Blossom is a structured research database and intelligence platform for psychedelic medicine, founded in 2019 by Floris Wolswijk and operated as a one-person company based in the Netherlands. The platform tracks clinical trials, peer-reviewed papers, compounds, topics, countries, stakeholders, people, training courses, and events across the psychedelic research landscape, with daily database updates and a curated corpus that reached 2,522 papers and 1,208 clinical trials by March 2026. Underlying technology is built on Sanity CMS for content management, Clerk for authentication, Stripe for billing, Resend for email, PostHog for analytics, and Vercel for hosting, with an OpenAPI 3.1 REST API and an MCP server for AI tool integration.

The product is monetized via a four-tier subscription model: Individual Researcher at $249/year, Research Team at $995/year for up to five seats, Enterprise Intelligence from $7,500/year with a concierge analyst and quarterly briefings, and a pay-what-you-can Access Program for academic and nonprofit users. Distribution is hybrid: product-led self-serve through the website with Stripe checkout, enterprise direct sales for high-ACV contracts, API and RSS integrations with 10 partner organizations (including Delphi, Drug Science, MIND Foundation, Psychedelic Alpha, and TheraPsil), and embedded AI connectors via Claude Desktop, Cursor, and Windsurf. The company serves academic researchers, clinicians, investors, and pharma organizations making strategic decisions in psychedelic medicine, and is privately held with no external funding, parent company, or subsidiaries.

Name

Blossom

Legal name

Blossom

Website

https://blossomanalysis.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Blossom is a one-person, Netherlands-based research database and intelligence platform for psychedelic medicine, tracking 2,522 papers, 1,208 clinical trials, compounds, countries, and stakeholders, monetized via Individual ($249/yr), Team ($995/yr), and Enterprise ($7,500+/yr) subscriptions for researchers, clinicians, and pharma investors.

Ownership category

akta.pro rank

Product category

Research Intelligence Software

NAICS

Software Publishers (513210)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)

akta.pro secondary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Psychedelic research database
• Clinical trial tracking
• Research intelligence platform
• Subscription research software
• Evidence-based research tools

Headquarters

HQ city

Not specified

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Individual Subscription: Annual subscription for solo researchers, clinicians, and serious readers. $249/year or $21/month equivalent. Includes full research database access, Pro filters, paper/trial tracking, historical coverage, and light data request support.
2. Team Subscription: Annual subscription for labs, clinics, and small teams at $995/year ($83/month equivalent). Up to 5 user licenses, team onboarding, priority data requests, and shared access.
3. Enterprise Intelligence: Custom annual contracts starting from $7,500/year for large organizations. Includes firm-wide access, advanced filtering, custom data pulls, priority support, and 1-on-1 concierge analyst.
4. Access Program: Pay-what-you-can subscription for students, academic researchers, and nonprofit organizations. Full professional access at reduced pricing.
5. API and Data Services: Programmatic access to research database via API. Free tier with 100 requests/minute, Pro tier with 500 requests/minute. Includes CSV downloads, dataset exports, and partner integrations.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Blossom operates a subscription-based research database and intelligence platform for psychedelic medicine, tracking clinical trials, peer-reviewed papers, compounds, topics, countries, stakeholders, and regulatory developments with daily updates. The platform offers tiered subscription access (Individual, Team, Enterprise), a public Research API, an MCP server for AI tool integration, and analytical tools including cross-trial results comparison, drug development pipeline views, and co-authorship network visualizations.

Product overview

Blossom is a structured research database for psychedelic medicine, tracking the full arc from clinical trials and peer-reviewed papers through to regulatory filings, therapy protocols, access policies, and real-world clinics. The core Blossom Research Database is a unified intelligence layer offering daily updates across papers, trials, compounds, topics, countries, stakeholders, people, courses, events, and research networks. Access is tiered: Individual Researcher ($249/year), Research Team ($995/year for up to 5 seats), Enterprise Intelligence (from $7,500/year for firm-wide access), and an Access Program (pay-what-you-can for academics/nonprofits). The platform bundles analysis tools including Enterprise Intelligence Briefings (quarterly competitive-intelligence briefings), Results Explorer (cross-trial outcome comparisons), Research Snapshot (one-page topic overviews), Clinical Guidelines (competency maps, training-evidence gap index, standards crosswalks for Oregon, Colorado, RANZCP), Ask Beta (AI research assistant with saved conversation threads), Research Network (interactive co-authorship graphs), Atlas (facility-level trial site mapping for 900+ sites), Top 10 Papers (curated citation lists), Drug Development Pipeline (59 developers on one timeline), Research Journey Timelines (for 6 compounds), Drug Development Catalysts (milestone calendar), Patent Library, Government Funding Catalogue, Pink Elephant Review (training programme assessment dashboard), Dose Summaries, Adverse Event Reports, Research Collections (compound x topic evidence pages), and Psychedelic Courses (training directory with course editions). The Research API provides programmatic access to all datasets in JSON/CSV/Parquet formats. An MCP Server enables Pro subscribers to query the database from AI tools (Claude Desktop, Cursor, Windsurf). RSS feeds support WordPress integration. The platform was rebuilt in March 2026 with v1.1.0 and originally launched in November 2025 as v0.1.0.

Differentiator

Problem solved

Functional benefit

Products and services

• Blossom Research Database (Core Platform) Unified intelligence platform for psychedelic medicine tracking clinical trials, peer-reviewed papers, compounds, topics, countries, stakeholders, people, courses, and events with daily database updates, advanced filtering, and analytical tools for researchers, clinicians, investors, and pharma organizations.
• Research API Public REST API providing programmatic access to papers, clinical trials, compounds, topics, countries, persons, journals, stakeholders, network data, evidence matrices, and downloadable CSV/JSON/Parquet datasets. Free tier with 100 requests/minute, Pro tier with 500 requests/minute. Authentication via Clerk JWT Bearer tokens with OpenAPI 3.1 specification.
• Access Program Pay-what-you-can subscription program providing full professional database access for students, academic researchers, and nonprofit organizations, offering identical access to the Individual Researcher tier for academic and public-good purposes.

Quantifiable outcome

• 67+ active trials tracked in depression with 12% growth year-over-year
• +1 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability9 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered core.

• DelphicoreStrategic or Co-development PartnerDelphi is listed as a partner organization. Floris Wolswijk works as a facilitator and consultant at Delphi alongside running Blossom, creating a close strategic relationship.
• Drug SciencecoreGTM or Marketing PartnerListed as a partner organization in Blossom's partner network, representing a key psychedelic research organization in the ecosystem.
• HorizonscoreGTM or Marketing PartnerPartner organization in Blossom's network, representing a psychedelic research and education platform.
• Lucid NewscoreGTM or Marketing PartnerPartner organization providing psychedelic research coverage and journalism.
• Microdosing InstitutecoreGTM or Marketing PartnerPartner organization focused on microdosing research and education.
• MIND FoundationcoreGTM or Marketing PartnerPartner organization representing a major European psychedelic research nonprofit.
• OPEN FoundationcoreGTM or Marketing PartnerPartner organization representing a key psychedelic research foundation.
• Psychedelic AlphacoreGTM or Marketing PartnerPartner organization providing psychedelic research analysis and intelligence. Josh Hardman, Founder of Psychedelic Alpha, is quoted endorsing Blossom.
• Psychedelics TodaycoreGTM or Marketing PartnerPartner organization representing a leading psychedelic media and education platform.
• TheraPsilcoreGTM or Marketing PartnerPartner organization focused on psychedelic therapy access and advocacy.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Drug Science: UK-based independent scientific body covering drug policy and harms research, including a dedicated psychedelic medicine program. Comparable as a psychedelic-research reference ecosystem, though broader in scope (all drugs) and non-commercial.
• PubMed: The National Library of Medicine's free biomedical literature database — the upstream source for Blossom's 2,522-paper corpus. Comparable as the free, broader incumbent that Blossom must continuously out-curate to retain paying users.
• MAPS (Multidisciplinary Association for Psychedelic Studies): The long-established psychedelic research nonprofit focused on MDMA-assisted therapy. Comparable as a primary-source publisher of psychedelic clinical trial results that Blossom aggregates into its database.
• ClinicalTrials.gov: The U.S. government clinical trial registry that is the upstream source for many of Blossom's 1,208 tracked trials. Comparable as the foundational trial database Blossom curates and contextualizes for paying subscribers.

Emerging players

• MIND Foundation: European psychedelic research and training nonprofit that publishes research summaries and runs psychedelic therapy training. Overlaps with Blossom in psychedelic research dissemination and is a listed Blossom partner, but Blossom sells the data infrastructure MIND and peers rely on.
• Psychedelics Today: Psychedelic education, media and research commentary platform. Comparable as a content-distribution partner and adjacent producer of research commentary that competes for the same audience of researchers and clinicians.
• Chacruna Institute: Psychedelic research, education and equity nonprofit that curates psychedelic scholarship and convenes researchers. Comparable as a curated psychedelic-knowledge publisher in adjacent (sociocultural) territory to Blossom's scientific focus.

Direct peers

• Psychedelic Alpha: Paid intelligence and analysis subscription covering the psychedelic medicine industry. The closest direct competitor and partner — Psychedelic Alpha focuses on commercial/investor intelligence while Blossom focuses on the research/clinical intelligence layer underneath it.

Others

• Delphi: Psychedelic training and strategic advisory organization where Blossom's founder also consults. Not a competitor but a strategic partner and a channel through which Blossom reaches enterprise and clinical audiences.

Regional players

• OPEN Foundation: Dutch psychedelic research foundation listed as a Blossom partner. Comparable as a Europe-anchored psychedelic research organization whose publications feed Blossom's research-curation pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/blossomact

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blossom